Pine Labs IPO Day 2 Subscription Status LIVE: Issue Subscribed 17%, GMP at 2% & Application Guide
Pine Labs IPO Day 2 Subscription Status LIVE: As per Pine Labs IPO Day 2 subscription status LIVE updates, the issue continues to attract attention at cautious pace, with investor appetite being monitored closely after a rather muted Day 1. The Pine Labs IPO GMP eased down to ₹4 today, indicating mild interest.
Here’s the breakdown of the Pine Labs IPO Day 2 Subscription Status LIVE & Day 1 subscription status and what we know about the current market mood.
Pine Labs IPO Day 2 Subscription Status LIVE
| Day | Overall Subscription | Retail Investors (RII) | Non-Institutional Investors (NII) | Qualified Institutional Buyers (QIB) | Notes |
|---|---|---|---|---|---|
| Day 1 (7 Nov 2025) | ~0.13x (13 %) | ~0.54x (54 %) | ~0.07x (7 %) | ~0.02x (2 %) | Employee portion notably stronger at ~2.96x |
| Day 2 (10 Nov 2025) | ~0.17x (17%) | ~0.71x (71%) | ~0.09x (9%) | ~0.02x(2%) | Employee portion stronger at ~3.86x |
Key Take-aways:
- As per Pine Labs IPO Day 2 subscription status LIVE updates; QIB demand is particularly low so far, which is unusual for large fintech issues.
- Retail investors appear more active, but still far from oversubscribed.
- Grey market indications (see next section) show that listing expectations are moderate, not showing the euphoria seen in some recent tech IPOs.
Pine Labs IPO GMP Today
Grey Market Premium (GMP) is a useful informal gauge of investor sentiment ahead of listing. For Pine Labs:
- Ahead of the issue opening, GMP was quoted at around ₹12 over the upper band (~5.4%).
- As things progressed, GMP softened and was reported at ~₹17 (~7.7%) in one source.
- Pine Labs IPO GMP today has dipped further to ~₹4 (~2%) above the upper band.
- The issue’s price band: ₹210 to ₹221 per share.
Interpretation:
A Pine Labs IPO GMP today of around +2% suggests that the market expects only a modest listing gain. The relatively low premium signals caution—investors appear treating this IPO more conservatively than some high-flying issues.
How to Apply for the Pine Labs IPO?
If you’re considering applying for the issue, here’s a crisp, step-by-step guide tailored for Indian retail investors:
- Check eligibility — You must have a demat account and be able to apply via ASBA (Application Supported by Blocked Amount) or broker platform.
- Verify lot size & amount — For Pine Labs, the minimum lot is 67 shares. At the upper band ₹221, that’s ~₹14,807 for one lot.
- Log in to your bank/broker IPO application section — Select the Pine Labs IPO, fill in number of lots you want to apply for, and confirm price band or cut-off.
- Block funds via ASBA — Your application amount will be blocked and only debited if allotment happens.
- Submit your bid before closing time — The issue closes on Tuesday, 11 November 2025.
- Allotment & listing — Allotment expected by 12 November 2025, and listing likely on 14 November 2025.
Practical little tips:
- Choose cut-off price if you’re okay with band range; otherwise specify a price within band.
- Applying early in the window can avoid server-rush, though final subscription counts matter more.
- Consider diversification: giant fintech IPOs may offer potential, but also come with valuation risk.
Final Thoughts
The Pine Labs IPO is definitely one to watch for Indian fintech watchers. With the subscription opening showing moderate interest and grey-market indication pointing to a modest premium, the listing may deliver modest gains rather than blockbuster returns.
Retail investors still have a window if they believe in the company’s long-term story — but they should weigh valuation carefully and apply with a clear trading plan (or long-term hold mindset).
Given the current data:
- Pine Labs IPO Day 2 subscription status LIVE was modest (~0.17x).
- GMP trending around +2%.
- This signals cautious investor sentiment rather than full-on bonanza.
Click Here to know more market & IPO related news and updates.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
